Truscreen Strengthens Market Presence Central Europe

NZX Announcement

5 August 2020

TruScreen strengthens its market presence in central and eastern Europe

As part of the rationalisation of its distributors network, Truscreen Limited (NZX: TRU) (“the
Company”) is pleased to announce that it has appointed prominent medical device distributor
Aspironix, s.r.o (Aspironix) as its exclusive distributor for Czech Republic, Slovakia, and Poland.

The territories of Czech Republic, Slovakia, and Poland, have a combined cervical cancer addressable
screening population of over 17.9
1
million women, presenting a significant market opportunity for the
Company.

Asprionix is a well-established specialised medical device distributor based in Prague, with a rapidly
growing turnover and increasing presence in central and eastern Europe.

Together with Aspironix, the Company will develop a comprehensive market access plan and have
begun preliminary Key Opinion Leaders (KOL) engagement for the region.

Truscreen CEO, Victoria Potarina, said “The distribution agreement with Aspironix will enable us to
significantly expand our distribution capabilities in central and eastern Europe, bringing Truscreen’s
latest real-time cervical cancer screening technology to the women of Czech Republic, Slovakia and
Poland.

The rationalisation of our distributor portfolio will see established and committed medical device
distributors, like Aspironix partnering with Truscreen to bring our Truscreen cervical cancer screening
technology to the millions of women who are currently not covered by effective cervical cancer
screening.”

- ENDS –

For more information, visit www.truscreen.com or contact:
Victoria Potarina
Chief Executive Officer
victoriapotarina@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com









1.
https://www.cia.gov/library/publications/the-world-factbook/

About TruScreen:
TruScreen is a Cervical Cancer Screening Device which
offers the latest technology in cervical screening,
providing real-time, accurate detection of pre-
cancerous and cancerous cervical cells to help improve
the health and well-being of women around the world.
TruScreen’s real-time cervical cancer technology
utilises a digital wand which is placed on the surface of
the cervix to measure electrical and optical signals from
the surrounding tissues. A sophisticated proprietary
algorithm framework is utilised to detect pre-cancerous
change, or cervical intra-epithelial neoplasia (CIN), by
optical and electrical measurement of cervical tissue.

TruScreen offers an alternative approach to cervical screening, resolving many of the ongoing
issues with Pap tests, including failed samples, poor patient follow-up, patient discomfort and
the need for supporting laboratory infrastructures. As such, TruScreen’s target market is low-
and middle-income countries where no large-scale cervical cancer screening programs and
infrastructure are in place, such as China, Mexico, Africa, Russia and India. TruScreen’s cervical
cancer screening device is CE-marked and certified for use throughout Europe and CFDA-
approved for sale in China. The global market potential for TruScreen is significant.

For more information, visit our website at www.truscreen.com
Watch our video on TruScreen: http://truscreen.com/truscreen-the-company/truscreen- ultra-
video/